


## GNE-7915 tosylate

<b>Cat. No.:</b>	HY-18163A
<b>CAS No.:</b>	2070015-00-6
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>29</sub> F <sub>4</sub> N <sub>5</sub> O <sub>6</sub> S
<b>Molecular Weight:</b>	615.6
<b>Target:</b>	LRRK2
<b>Pathway:</b>	Autophagy
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 50 mg/mL (81.22 mM)  
 H<sub>2</sub>O : < 0.1 mg/mL (insoluble)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.6244 mL	8.1222 mL	16.2443 mL
	5 mM	0.3249 mL	1.6244 mL	3.2489 mL
	10 mM	0.1624 mL	0.8122 mL	1.6244 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: 2.5 mg/mL (4.06 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: 2.5 mg/mL (4.06 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (4.06 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC<sub>50</sub> of 9 nM.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 9 nM<sup>[1]</sup> (LRRK2)

#### In Vitro

Maintaining the methoxy/fluoro arrangement at C-2'/C-5' and varying aminoalkyl R1 substitution results in single-digit nanomolar LRRK2 cellular activities for GNE-7915 and compound 19. Expanded Invitrogen kinase profiling (187 kinases) at 0.1 μM for both GNE-7915 (100-fold over LRRK2 Ki) and 19 (250-fold over LRRK2 Ki) results in only TTK showing greater than

50% inhibition. Selectivity profiling using the DiscoverX KinomeScan55 competitive binding assay panel, which includes 392 unique kinases, is also performed for GNE-7915 at 0.1  $\mu$ M. Binding of >50% probe displacement is detected for 10 kinases and of >65% for only LRRK2, TTK, and ALK, further supporting the excellent LRRK2 selectivity for GNE-7915. Cerep receptor profiling, including expanded brain panels, suggests that GNE-7915 and 19 only inhibit 5-HT<sub>2B</sub> with >70% inhibition at 10  $\mu$ M. GNE-7915 and 19 are confirmed to be moderately potent 5-HT<sub>2B</sub> antagonists in vitro functional assays<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Stem Cell Reports. 2022 Sep 12;S2213-6711(22)00423-4.
- Hum Mol Genet. 2017 Jul 15;26(14):2747-2767.
- bioRxiv. 2023 Jan 9.
- bioRxiv. 2020 Apr.
- Programa Oficial de Doctorado en Biomedicina. Universidad de Granada. 5-Jul-2017.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Kavanagh ME, et al. The development of CNS-active LRRK2 inhibitors using property-directed optimisation. *Bioorg Med Chem Lett.* 2013 Jul 1;23(13):3690-6.
- [2]. Estrada AA, et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. *J Med Chem.* 2012 Nov 26;55(22):9416-33.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA